Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide.Glucagon-like peptide-1 receptor agonists gained approval as drugs to treat diabetes and obesity starting in the 2000s.
The combined clinical benefits and mechanistic insights position GLP-1RAs as leaders in addressing glycemic dysregulation and liver diseases, suggesting a transformative approach to the association between metabolic disorders and liver conditions.
Molecular profiling revealed semaglutide-coordinated transcriptional and protein-level reversal of disease signatures. Together, the data using mouse models of MASH reveal an EC-specific, weight-loss-independent, semaglutide-regulated, GLP-1R-dependent intrahepatic network for improving liver health.
Family medicine clinicians frequently encounter patients with metabolic-associated steatotic liver disease (MASLD) who may not meet criteria for GLP-1 therapy based on BMI or glycemic thresholds alone, and evidence of direct hepatic benefit independent of weight loss expands the clinical rationale for prescribing these agents in that population. Understanding that GLP-1 receptor agonists exert ...
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as a promising therapeutic option beyond their established role in managing type 2 diabetes mellitus (T2DM) and obesity. Recent research has highlighted their beneficial effects on liver, kidney, and cardiovascular health, mediated by both direct and indirect mechanisms. In the liver, GLP-1 RAs contribute to the improvement of ...
Glucagon-like Peptide 1 Receptor Agonist (GLP-1 RA) treatments have emerged as potential agents for noted benefits in many aspects related to the pathology and progression of MASLD.
GLP-1 agonists are approved for the treatment of diabetes and for obesity. Why are patients with non-alcoholic fatty liver disease (NAFLD) suddenly being prescribed GLP-1 agonists and what are the effects on the liver?
"This is the first time that GLP-1 receptor agonists have been shown to regulate alcohol metabolism in the liver," says principal investigator Wajahat Mehal, MD, professor of medicine (digestive diseases) at YSM. "If you're taking semaglutide, then your body will likely handle alcohol differently."
